ab1678 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab1678 は 9 報の論文で使用されています。

  • Yea SS  et al. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. PLoS One 9:e99486 (2014). WB . PubMed: 24915189
  • Suárez-Fueyo A  et al. Inhibition of PI3Kd reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. J Immunol 193:544-54 (2014). Mouse . PubMed: 24935930
  • Aksoy E  et al. The p110d isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol 13:1045-54 (2012). IP ; Mouse . PubMed: 23023391
  • Sanchez CG  et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13:R21 (2011). WB ; Human . PubMed: 21362200
  • Conte E  et al. Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms. PLoS One 6:e24663 (2011). WB ; Human . PubMed: 21984893
  • Suárez-Fueyo A  et al. Enhanced phosphoinositide 3-kinase d activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol 187:2376-85 (2011). PubMed: 21810603
  • Ramadani F  et al. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci Signal 3:ra60 (2010). WB ; Mouse . PubMed: 20699475
  • Low PC  et al. Phosphoinositide 3-kinase {delta} regulates membrane fission of Golgi carriers for selective cytokine secretion. J Cell Biol : (2010). PubMed: 20837769
  • Park S  et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22:1698-706 (2008). PubMed: 18548104

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"